3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Multiple Myeloma
238
Precursor Cell Lymphoblastic Leukemia-Lymphoma
46
Recurrence
35
Burkitt Lymphoma
23
Neoplasms
20
Neoplasms, Plasma Cell
17
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
15
Immunoglobulin Light-chain Amyloidosis
13
Leukemia
12
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
10
Lymphoma
10
Lymphoma, Large B-Cell, Diffuse
9
Lung Neoplasms
9
Carcinoma, Non-Small-Cell Lung
9
Prostatic Neoplasms
8
Leukemia, Biphenotypic, Acute
8
Neoplasm Metastasis
7
Lymphoma, Non-Hodgkin
7
Breast Neoplasms
7
Lymphoma, B-Cell
6
Smoldering Multiple Myeloma
5
Nausea
5
Leukemia, Myeloid, Acute
5
Hodgkin Disease
5
Brain Neoplasms
5
Waldenstrom Macroglobulinemia
4
Neoplasm, Residual
4
Lymphoma, T-Cell, Peripheral
4
Lymphoma, Mantle-Cell
4
Amyloidosis
4
Interventions
pomalidomide
2
Dexamethasone
2
venetoclax
1
pirtobrutinib
1
pembrolizumab
1
ibrutinib
1
fludarabine phosphate
1
fludarabine
1
daratumumab
1
acalabrutinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Chromosome 17 deletion
×
Dexamethasone
×
1 year
×
Clear all
NCT01745640
2026-02-05
IFM2010-02
University Hospital, Lille
Phase 2
Completed
63 enrolled
NCT04124497
2025-08-08
DPd
Fondazione EMN Italy Onlus
Phase 2
Active not recruiting
45 enrolled